CL2025001072A1 - Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer. - Google Patents

Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer.

Info

Publication number
CL2025001072A1
CL2025001072A1 CL2025001072A CL2025001072A CL2025001072A1 CL 2025001072 A1 CL2025001072 A1 CL 2025001072A1 CL 2025001072 A CL2025001072 A CL 2025001072A CL 2025001072 A CL2025001072 A CL 2025001072A CL 2025001072 A1 CL2025001072 A1 CL 2025001072A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
treating cancer
compounds
tricyclic compounds
tricyclic
Prior art date
Application number
CL2025001072A
Other languages
English (en)
Inventor
Bordas Vincent
Furegati Markus
Hamon Jacques
Hans-Hermann Hinrichs Juergen
HONG Ziyue
LIMA Fabio
LIMAM Fatma
Moebitz Henrik
NOCITO Sandro
Schmiedeberg Niko
Schoepfer Joseph
Strang Ross
Zecri Frédéric
YU Huangchao
Zhang Yong
Yang Xinkan
Zhang Sisi
Li Wei
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2025001072A1 publication Critical patent/CL2025001072A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto, o una sal farmacéuticamente aceptable del mismo, de la fórmula (I): en donde R1, R2, R3, x, R4, R5, y, R, M, W, L, V, T, Y, J, K y A han sido definidos en la presente, usos terapéuticos de dichos compuestos, usos de dichos compuestos como productos químicos de investigación, una composición farmacéutica y combinaciones que comprenden dichos compuestos, y métodos de fabricación de los compuestos de la invención.
CL2025001072A 2022-10-12 2025-04-09 Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer. CL2025001072A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2022124865 2022-10-12
EP22208192 2022-11-17
US202363494033P 2023-04-04 2023-04-04
CN2023108913 2023-07-24

Publications (1)

Publication Number Publication Date
CL2025001072A1 true CL2025001072A1 (es) 2025-08-01

Family

ID=88315575

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001072A CL2025001072A1 (es) 2022-10-12 2025-04-09 Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer.

Country Status (17)

Country Link
US (1) US20240245694A1 (es)
EP (1) EP4601746A1 (es)
JP (1) JP2025536259A (es)
KR (1) KR20250079023A (es)
CN (1) CN120077048A (es)
AR (1) AR130727A1 (es)
AU (1) AU2023361889A1 (es)
CL (1) CL2025001072A1 (es)
CR (1) CR20250187A (es)
DO (1) DOP2025000087A (es)
IL (1) IL319660A (es)
JO (1) JOP20250072A1 (es)
MX (1) MX2025004220A (es)
PE (1) PE20251323A1 (es)
TW (1) TW202417450A (es)
UY (1) UY40470A (es)
WO (1) WO2024079623A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024286830A1 (en) 2023-06-08 2025-12-04 Nimbus Wadjet, Inc. Wrn inhibitors
EP4755890A1 (en) * 2023-08-01 2026-06-10 Haisco Pharmaceutical Group Co., Ltd. Oxo-tricyclic derivative and pharmaceutical use thereof
WO2025073792A1 (en) 2023-10-02 2025-04-10 Forx Therapeutics Ag Wrn inhibitory compounds
AU2024410908A1 (en) 2023-12-29 2026-07-16 Suzhou Genhouse Bio Co., Ltd. Fused ring compound, pharmaceutical composition containing same and use thereof
TW202539684A (zh) * 2024-01-15 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 一種三唑並嘧啶類衍生物、其製備方法與應用
WO2025162478A1 (en) * 2024-02-04 2025-08-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
TW202547484A (zh) 2024-04-10 2025-12-16 瑞士商諾華公司 藥物組合及其用途
WO2025218781A1 (en) * 2024-04-19 2025-10-23 Insilico Medicine Ip Limited Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof
WO2025223396A1 (en) * 2024-04-22 2025-10-30 3H Pharmaceuticals Co., Ltd. Fused tricyclic compounds and methods of use thereof
WO2025232693A1 (en) * 2024-05-08 2025-11-13 Nuphase Therapeutics (Shanghai) Limited., Co. Novel compounds, compositions comprising the same and uses thereof
WO2025237361A1 (zh) * 2024-05-16 2025-11-20 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025237389A1 (zh) * 2024-05-17 2025-11-20 成都微芯药业有限公司 三环wrn抑制剂、其制备方法及其应用
WO2025242186A1 (zh) * 2024-05-24 2025-11-27 浙江海正药业股份有限公司 氮杂三环类衍生物及其制备方法和用途
WO2025247335A1 (en) * 2024-05-30 2025-12-04 Allorion Therapeutics Inc Compounds and use thereof as wrn inhibitors
WO2026003380A1 (en) 2024-06-28 2026-01-02 Forx Therapeutics Ag Wrn inhibitory compounds
CN121426817A (zh) * 2024-07-10 2026-01-30 广州科恩泰生物医药科技有限公司 一种抑制wrn解旋酶的含氮杂环衍生物、含其的药物组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2008027990A1 (en) * 2006-08-29 2008-03-06 Trustees Of Boston University Therapeutic methods using wrn binding molecules
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2022093820A1 (en) * 2020-10-28 2022-05-05 Genentech, Inc. Substituted morpholine compounds
AR125966A1 (es) * 2021-05-26 2023-08-30 Novartis Ag Nuevos compuestos bicíclicos y sus usos
WO2024105610A1 (en) * 2022-11-18 2024-05-23 Novartis Ag Pharmaceutical combinations and uses thereof
US20260184716A1 (en) * 2022-11-23 2026-07-02 Novartis Ag Solid forms of a fused pyridine for the treamtent of cancer
US20250368646A1 (en) * 2024-05-28 2025-12-04 Nimbus Wadjet, Inc. Tricyclic fused wrn inhibitors

Also Published As

Publication number Publication date
KR20250079023A (ko) 2025-06-04
AR130727A1 (es) 2025-01-15
EP4601746A1 (en) 2025-08-20
CN120077048A (zh) 2025-05-30
WO2024079623A1 (en) 2024-04-18
TW202417450A (zh) 2024-05-01
MX2025004220A (es) 2025-05-02
PE20251323A1 (es) 2025-05-16
JOP20250072A1 (ar) 2025-04-10
CR20250187A (es) 2025-06-04
UY40470A (es) 2024-05-15
DOP2025000087A (es) 2025-06-15
IL319660A (en) 2025-05-01
US20240245694A1 (en) 2024-07-25
JP2025536259A (ja) 2025-11-05
AU2023361889A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
DOP2025000087A (es) Compuestos tricíclicos y sus usos
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
CL2021003202A1 (es) Compuestos de pirrolidina
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
MX2026001061A (es) Inhibidores de la fosfatidilinositol 3-cinasa (pi3k)
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
CO2025005872A2 (es) Compuestos tricíclicos y sus usos
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
CO2021017202A2 (es) Compuestos tricíclicos
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
MX2025008259A (es) Inhibidores de prmt5-mta
AR127496A1 (es) Compuestos de cd73
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
DOP2025000235A (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
AR131842A1 (es) Métodos para tratar gliomas
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
UY39532A (es) Compuestos de (aza)benzotiazolil-pirazol sustituidos
AR129171A1 (es) Compuestos heteroaromáticos
CO2026002539A2 (es) Compuestos para la inhibición de fgfr
AR131249A1 (es) Derivados de heteroarilo bicíclicos útiles como agentes anticancerígenos